

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

604-781

10/584,470

APPLICANT

CHIBBER

FILING DATE

GROUP

June 22, 2006

Unassigned



(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,684,134	11/1997	Fukuda et al			
	6,593,301	07/2003	Ma et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
0 251 197 A2	01/1988	EP			
2 027 434 C1	01/1995	Russian Federation			X
WO 95/17182 A1	06/1995	WO			
WO 95/35294 A1	12/1995	WO			
WO 97/47298 A1	12/1997	WO			
WO 00/31109 A1	06/2000	WO			
WO 03/070261 A1	08/2003	WO			
WO 2004/062675 A1	07/2004	WO			
WO 2004/064852 A1	08/2004	WO			
WO 2004/093662 A2	11/2004	WO			
WO 2005/060977 A1	07/2005	WO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Co-Pending U.S. Application Serial No. 11/472,554, filed June 22, 2006.
	Co-Pending U.S. Application Serial No. 11/481,255, filed July 6, 2006.
	Co-Pending U.S. Application Serial No. 11/481,256, filed July 6, 2006.
	Chibber, R., et al; "Activity of the Glycosylating Enzyme, Core 2 GlcNAc (β1,6) Transferase, is Higher in Polymorphonuclear Leukocytes From Diabetic Patients Compared With Age-Matched Control Subjects"; <i>Diabetes</i> ; Vol. 49; pp. 1724-1730 (2000).
	Chibber, R., et al; "Protein Kinase C β2-Dependent Phosphorylation of Core 2 GlcNAc-T Promotes Leukocyte-Endothelial Cell Adhesion"; <i>Diabetes</i> ; Vol. 52; pp. 1519-1527 (2003).
	Ellies, L.G., et al; "Core 2 Oligosaccharide Biosynthesis Distinguishes between Selectin Ligands Essential for Leukocyte Homing and Inflammation"; <i>Immunity</i> ; Vol. 9, pp. 881-890 (1998).
	Goekjian, P.G., et al; "Protein kinase C inhibitors as novel anticancer drugs"; <i>Expert Opin. Investig. Drugs</i> ; Vol. 10, No. 12; pp. 2117-2140 (2001).
	Hartung, Hans-Peter, MD; et al; "Circulating Adhesion Molecules and Tumor Necrosis Factor Receptor in Multiple Sclerosis: Correlation with Magnetic Resonance Imaging"; <i>Annals of Neurology</i> ; Vol. 38, No. 2; pp. 186-193 (1995).
	Hindsgaul, O., et al; "Evaluation of Deoxygenated Oligosaccharide Acceptor Analogs as Specific Inhibitors of Glycosyltransferases"; <i>The Journal of Biological Chemistry</i> ; Vol. 266, No. 27; pp. 17858-17862 (1991).
	Joshi, J., et al; "Chemistry of Ayurvedic Crude Drugs: Part VIII ^a -Shatavari-2: Structure Elucidation of Bioactive Shatavarin-I & other Glycosides ^{b,c} "; <i>Indian Journal of Chemistry</i> ; Vol. 27B; pp. 12-16 (1988).
	Kim, S.Y., et al; "Inhibition of Mouse Ear Edema by Steroidal and Triterpenoid Saponins"; <i>Arch Pharm Res.</i> ; Vol. 22, No. 3, pp. 313-316 (1999).
	Kuhns, W., et al; "Processing O-glycan core 1, Galβ1-3GalNAcα-R. Specificities of core 2, UDP-GlcNAc: Galβ1-3GalNAc-R(GlcNAc to GalNAc) β6-N-acetylglucosaminyltransferase and CMP-sialic acid: Galβ1-3GalNAc-R α3-sialyltransferase"; <i>Glycoconjugate Journal</i> ; Vol. 10; pp. 381-394 (1993).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Initial this form with next communication to application.

Sheet 2 of 2

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

604-781

10/584,470

APPLICANT

CHIBBER

(Use several sheets if necessary)

FILING DATE

TC/A.U.

June 22, 2006

Unassigned

	Matsuda, H., et al; "Protective Effects of Steroid Saponins from <i>Paris polyphylla</i> var. <i>yunnanensis</i> on Ethanol- or Indomethacin-Induced Gastric Mucosal Lesions in Rats: Structural Requirement for Activity and Mode of Action"; <i>Bioorganic & Medicinal Chemistry Letters</i> ; Vol. 13; pp. 1101-1106 (2003).
	Orlacchio, A., et al; "Activity levels of a β 1, 6 N-acetylglucosaminyltransferase in lymphomonocytes from multiple sclerosis patients"; <i>Journal of Neurological Sciences</i> ; Vol. 151; pp. 177-183 (1997).
	Toki, D., et al; "Inhibition of UDP-GlcNAc:Gal β 1-3GalNAc-R (GlcNAc to GalNAc) β 6-N-acetylglucosaminyltransferase from acute myeloid leukaemia cells by photoreactive nitrophenyl substrate derivatives"; <i>Biochemical and Biophysical Research Communications</i> ; Vol. 198, No. 2; pp. 417-423 (1994).
	Washington, R., et al; "Expression of Immunologically Relevant Endothelial Cell Activation Antigens on Isolated Central Nervous System Microvessels from Patients with Multiple Sclerosis"; <i>Ann. Neurol</i> ; Vol. 35, No. 1; pp. 89-97 (1994).
	Li, Cheng-Ming, et al; "Development of monoclonal antibodies against bovine mucin core 2 β 6 N-acetylglucosaminyltransferase"; <i>Glycoconjugate Journal</i> ; Vol. 16; pp. 555-562 (1999).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

CHIBBER

Atty. Ref.: LCM-604-781

Serial No. 10/584,470

TC/A.U.: Unassigned

Filed: June 22, 2006

Examiner: Unassigned

For: CORE 2 GLCNAC-T INHIBITORS

* * * * *

February 9, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO/SB/08a as filed in co-pending Application Serial No. 11/472,554.


This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO/SB/08a and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:


Leonard C. Mitchard
Reg. No. 29,009

LCM:lff
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100